Gilead Sciences Inc., the company that developed the HIV drug Stribild, announced that its new medication, tenofovir alafenamide, was found to be more effective than Stribild based on two studies. In the first study, the percentage of patients who experienced a reduction of HIV virus level by using the new drug and Stribild was 93% and 92%, respectively. The second study shows a reduction by 91.6% for tenofovir alafenamide, and 88% for Stribild. The company planned for US and Europian approval for this drug. Based on your experience with HIV patients, what medication characteristics typically predict good compliance/adherence?
To read more, please visit Reuters.
Image courtesy of [dream designs] / FreeDigitalPhotos.net